CNS Pharmaceuticals, Inc.

What they do

CNS Pharmaceuticals, Inc. is a biotechnology company organized as a Nevada corporation in July 2017 and listed on the NASDAQ Capital Market under the symbol CNSP. In March 2026 the company announced a new corporate strategy focused on developing innovative therapies for serious diseases, stating it is leveraging the executive team's multi-functional experience. The 10-Q's forward-looking statements reference securing rights to new pipeline assets, obtaining funding to develop those assets, and conducting research and development and clinical trials through all phases of clinical development. The filings provided do not describe any currently marketed products or disclosed revenue-generating operations.

Revenue drivers

• No disclosed product revenue — The provided filings do not identify any marketed product or revenue-generating segment; the 10-Q discusses only pipeline assets, research and development, and clinical trials.
• Pipeline asset rights — Management's stated plan is to secure rights to new pipeline assets, which would be the basis for future development-stage value rather than current revenue.
• External funding — The company lists obtaining additional funding to develop pipeline assets as a forward-looking priority, alongside compliance with NASDAQ continued listing requirements.

Recent performance

Annual net loss was $14.5 million in 2021 and $15.3 million in 2022; the XBRL annual figures for 2023, 2024 and 2025 are reported as $-18,851, $-14,858 and $-15,987, respectively, which are inconsistent in scale with the prior years and should be verified against the filings. Operating cash flow was negative in each year shown: $-13.5M (2021), $-10.6M (2022), $-14.1M (2023), $-17.1M (2024) and $-13.8M (2025). Diluted EPS was $-16.5 (2021), $-11.22 (2022), $-12,509.11 (2023), $-466.89 (2024) and $-35.75 (2025). As of 2026-06-30 the company reported total assets of $21.9 million, total liabilities of $3.7 million, shareholder equity of $18.2 million and cash and equivalents of $20.0 million. The 10-Q MD&A describes only the corporate overview and risk discussion in the excerpt provided.

Strategy

In March 2026 the company announced a new corporate strategy focused on developing innovative therapies for serious diseases, leveraging the executive team's experience. Management's forward-looking statements center on securing rights to new pipeline assets, obtaining additional funding to develop pipeline assets, and advancing research and development and clinical trials through all phases, including regulatory approval of product candidates. Other stated priorities include maintaining compliance with NASDAQ Capital Market continued listing requirements, establishing or maintaining collaborations, licensing or other arrangements, and protecting intellectual property rights. The company also cites dependence on third-party manufacturers and the ability to attract and retain key personnel. Leadership changed in early 2026: Rami Levin became President and Chief Executive Officer and a director in January 2026, and Steve O'Loughlin became Chief Financial Officer in March 2026.

Risks

• Going-concern and funding need — The company reported operating cash outflows of $13.8 million in 2025 and lists obtaining additional funding to develop pipeline assets as a forward-looking priority.
• NASDAQ listing compliance — Management's forward-looking statements specifically flag the ability to maintain compliance with the NASDAQ Capital Market's continued listing requirements, including any new requirements approved in the future.
• No approved product — The provided excerpts disclose no marketed product or product revenue, leaving value dependent on clinical trials, regulatory review and approval of product candidates.
• Reliance on third parties — The company cites dependency on third-party manufacturers to supply or manufacture its products and compliance with obligations under intellectual property licenses with third parties.

Outlook

The 10-Q does not contain a results-of-operations or outlook section in the excerpt provided; it frames the company as pivoting to a new strategy announced in March 2026 focused on developing therapies for serious diseases. Management's stated forward-looking items are securing rights to new pipeline assets, obtaining additional funding, advancing clinical development and regulatory approval, and maintaining NASDAQ listing compliance. No specific timelines, trial readouts or revenue guidance appear in the provided source material.